How Did Oakridge International (ASX:OAK) Return to Profit in FY26 With 42% Higher Revenue?

Sonal Goyal

16 October 2026 10:53 PM AEDT

How Did Oakridge International (ASX:OAK) Return to Profit in FY26 With 42% Higher Revenue?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Revenue rose 42%, or $1,012,668, to $3,446,008, and profit after tax was $109,171 against a loss of $128,795 in FY25.
Cash rose to $637,641 from $468,939, and net Assets were $1,361,413, with no Dividend declared.
The profit is small relative to revenue, and the company attributes the Revenue growth mainly to increased Business development activity.

Oakridge International Limited (ASX:OAK), an Adelaide-based supplier of healthcare technology, released its Appendix 4E and Annual Report for the year ended 30 June 2026. The report was signed on 24 August 2026 and the financial statements have been audited with no qualification.

Results

Revenue from ordinary activities was $3,446,008, up 42% or $1,012,668 on the prior year, which the company attributes mainly to increased sales from business development activities. Profit attributable to owners was $109,171, up 185%, reversing a loss of $128,795. Net tangible assets per ordinary security were 4.08 cents, against 2.76 cents. No dividend was declared or paid in either year.

Balance sheet

Cash and cash equivalents were $637,641, against $468,939, an increase of $168,702 following a decrease of $492,636 the year before. Total assets were $2,123,849 against $1,606,097, and net assets were $1,361,413 against $902,246.

Business activity

Oakridge sells professional healthcare technology equipment and solutions to healthcare facilities, and develops and distributes its own nurse call hardware and software for hospitals, aged care, disability care and supported independent living. It continues to focus on assisted independent living technologies using its Internet of Things platform and is exploring emerging technology opportunities in IoT and healthcare.

Product development and delivery

The product roadmap is aligned with the evolving AS8311:2024 Nurse Call Standard. Work included enhancements to the NuCaMS and NuCaMS Enterprise platforms, completion of RTLS call point and resident pendant work, first-stage enterprise reporting, refined LED and LCD annunciator display modules, software development across administration, authentication, reporting and single sign-on with validated Microsoft Azure integration, and continued mobile application development.

The company reports a significant Volume of project work across multiple regions and care sites, from direct sales and an expanding partner channel, and says it evaluated extending its platform into a broader connected clinical care offering. It did not disclose order Backlog figures in the Appendix 4E.

Cash flow and strategy

Net cash increased by $168,702 during FY26, compared with a decrease of $492,636 the year before. The company progressed strategic planning for enterprise-grade reporting and AI-enabled capabilities for its NuCaMS platform and evaluated extending the platform into a broader connected clinical care offering that would combine workflow data with complementary consumables and non-invasive monitoring inputs. It continues to look for opportunities in IoT and healthcare technology.

Standards and channel

The product roadmap follows the AS8311:2024 Nurse Call Standard to support compliance and competitive positioning. The company says projects were delivered across multiple regions and care sites, with growth from direct sales and its partner channel. The Appendix 4E notes there were no significant changes in the nature of activities, and significant events after the balance date are set out in note 28 of the financial statements.

FAQs

Q: What did Oakridge (ASX:OAK) report for FY26?

A:Revenue of $3,446,008, up 42%, and a profit of $109,171.

Q: How does that compare with FY25?

A:FY25 was a loss of $128,795.

Q: What is the cash balance?

A:$637,641 at 30 June 2026.

Q: Was a dividend declared?

A:No dividend was declared or paid.

Q: What does the company sell?

A:Healthcare technology, including its own nurse call hardware and software such as NuCaMS.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.